DOCSLIB.ORG

7038.Full-Text.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
7038.Full-Text.Pdf [CANCER RESEARCH 63, 7038–7041, November 1, 2003] Advances in Brief Identification of COX17 as a Therapeutic Target for Non-Small Cell Lung Cancer1 Chie Suzuki, Yataro Daigo, Takefumi Kikuchi, Toyomasa Katagiri, and Yusuke Nakamura2 Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan Abstract Saccharomyces cerevisiae (7, 8). Although this small protein has been cloned or purified from mammals as well, including human, mouse, We have been investigating gene expression profiles in non-small cell and pig, its function in cancer cells or even in normal mammalian lung cancers (NSCLCs) to identify molecules involved in pulmonary somatic cells has not been established (8–10). carcinogenesis and select which genes or gene products might be useful as diagnostic markers or targets for new molecular therapies. Here we report Here we report functional characterization of COX17 in human evidence that the cytochrome c oxidase (CCO) assembly protein COX17 is lung tumors and in metabolism of normal mammalian cells. Our a potential molecular target for treatment of lung cancers. By semiquan- results suggest that overexpression of COX17 plays a significant role titative reverse transcription-PCR, we documented increased expression in development/progression of lung cancer and that this molecule of COX17 in all of 8 primary NSCLCs and in 11 of 15 NSCLC cell lines represents a potential target for development of novel therapeutic examined, by comparison with normal lung tissue. Treatment of NSCLC drugs. cells with antisense S-oligonucleotides or vector-based small interfering RNAs of COX17 suppressed expression of COX17 and also the activity of Materials and Methods CCO, and suppressed growth of the cancer cells. Because our data imply that up-regulation of COX17 function and increased CCO activity are Cell Lines. Fifteen human NSCLC cell lines were used in this study: A549, frequent features of lung carcinogenesis, we suggest that selective sup- NCI-H23, NCI-H522, LC174, LC176, LC319, PC14, PC3, PC9, NCI-H1435, pression of components of the CCO complex might hold promise for NCI-H1793, SK-LU-1, RERF-LC-AI, SK-MES-1, and NCI-H358. Human development of a new strategy for treating lung cancers. SAECs and NHDF cells were used as controls. All of the cancer cells were grown in monolayers in appropriate medium supplemented with 10% fetal Introduction bovine serum. SAECs and NHDF cells were grown in optimized medium (SAGM and FGM-2, respectively) purchased from Cambrex Bio Science Inc. Lung cancer is one of the most common cancers in the world. (Walkersville, MD). Primary NSCLCs were obtained with informed consent 3 NSCLC is by far the most common form, accounting for ϳ80% of from NSCLC patients, as described previously (5), and 8 samples were used in lung tumors (1). The overall 10-year survival rate remains as low as this study. 10% despite recent advances in multimodality therapy, because the Selection of a Candidate Gene and Analysis by Semiquantitative RT- majority of NSCLCs are not diagnosed until advanced stages (2). PCR. Using the gene expression profiles of 37 primary NSCLCs obtained Although chemotherapy regimens based on platinum are considered previously by cDNA microarray analysis (5), we selected genes that showed the reference standards for treatment of NSCLC, those drugs are able levels of expression that were 5-fold higher than in normal lung in Ͼ50% of to extend survival of patients with advanced NSCLC only ϳ6 weeks the tumors examined. The COX17 transcript was among them. To confirm (3). Numerous targeted therapies are being investigated for this dis- overexpression of COX17 by semiquantitative RT-PCR, total RNA was ex- tracted from cultured cells and clinical tissues using TRIzol reagent (Life ease, including tyrosine kinase inhibitors, but thus far promising Technologies, Inc., Gaithersburg, MD) according to the manufacturer’s pro- results have been achieved in only a limited number of patients, and tocol. The RNA preparations were treated with DNase I (Nippon Gene, Tokyo, some recipients suffer severe adverse reactions (4). By analyzing Japan) and reverse-transcribed to single-stranded cDNAs using oligo(dT)12–18 genome-wide expression profiles of 37 primary NSCLCs on a cDNA primer with Superscript II reverse transcriptase (Life Technologies, Inc.). We microarray containing 23,040 genes, we have been attempting to prepared appropriate dilutions of each single-stranded cDNA for subsequent identify more selective molecular targets for development of strate- PCR amplification by monitoring the ␤-2-microglobulin gene (B2M)asa gies for earlier diagnosis, treatment, and/or prevention of NSCLC (5). quantitative control. The primer sets for amplification were B2M-F (5Ј- In the course of those experiments we identified COX17 as one of the TTAGCTGTGCTCGCGCTACT-3Ј), B2M-R (5Ј-TCACATGGTTCACACG- Ј Ј Ј genes that was frequently overexpressed in lung tumors. GCAG-3 ) for B2M, and COX17-F (5 -GTGGACATCTAATTGAGGCC-3 ), Ј Ј COX17 is an M 8,000 protein that is essential for assembly of COX17-R (5 -GAAGATCTTCCACTAGTAATATT-3 ) for COX17. All of r the reactions involved initial denaturation at 94°C for 2 min followed by 22 functional CCO in yeast and for delivery of copper ions to the yeast (for B2M) or 27 cycles (for COX17) of 94°C for 30 s, 58–62°C for 30 s, and mitochondrion for insertion into the enzyme (6). Mutations among the 72°C for 45 s on a GeneAmp PCR system 9700 (Applied Biosystems, Foster six conserved cysteines of COX17 lead to respiratory defects in City, CA). AS S-Oligonucleotides. Two ϫ 105 cells from NSCLC line A549 plated Received 5/26/03; revised 8/15/03; accepted 8/29/03. onto six-well dishes were transfected with synthetic S-oligonucleotides (0.2 The costs of publication of this article were defrayed in part by the payment of page ␮M) corresponding to the COX17 gene, using Lipofectamine reagent (40 nM; charges. This article must therefore be hereby marked advertisement in accordance with Invitrogen, Carlsbad, CA), and maintained for 2 days in medium containing 18 U.S.C. Section 1734 solely to indicate this fact. 1 Supported in part by a “Research for the Future” Program Grant of The Japan Society 10% fetal bovine serum. Cell numbers and cell viability were evaluated, for the Promotion of Science (#00L01402; to Y. N.). respectively, by Giemsa staining and MTT assay, each in triplicate. The 2 To whom requests for reprints should be addressed, at Laboratory of Molecular sequences of the S-oligonucleotides were as follows: AS, 5Ј-TCTCCTTTCTC- Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, GATGATA-3Ј; and R, 5Ј-ATAGTAGCTCTTTCCTCT-3Ј. MTT assays were 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan. Phone: 81-3-5449-5372; Fax: 81-3-5449-5433; E-mail: yusuke@ims.u-tokyo.ac.jp. performed as described elsewhere (11). 3 The abbreviations used are: NSCLC, non-small cell lung cancer; CCO, cytochrome RNAi Assay. We had established a vector-based RNAi system, c oxidase; SAEC, small airway epithelial cell; NHDF, normal human dermal fibroblast; psiH1BX3.0, to direct the synthesis of siRNAs in mammalian cells, as reported RT-PCR, reverse transcription-PCR; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet- elsewhere (12). Ten ␮g of siRNA-expression vector was transfected using 30 razolium bromide; R, reverse; AS, antisense; RNAi, RNA interference; siRNA, small ␮ interfering RNA; GFP, green fluorescent protein; EGFP, enhanced green fluorescent l of Lipofectamine 2000 (Invitrogen) into NSCLC cell lines, A549 and protein. LC319. In this assay, Ͼ90% of the transfected cells expressed this synthetic 7038 Downloaded from cancerres.aacrjournals.org on September 24, 2021. © 2003 American Association for Cancer Research. COX17: A NOVEL TARGET FOR NSCLC TREATMENT siRNA, and endogenous expression of COX17 was effectively suppressed. The ulations, all of which had been purified by laser-capture microdissec- transfected cells were cultured for 5 days in the presence of appropriate tion (5). We additionally examined expression of this gene using concentrations of geneticin (G418). Cell numbers and viability were measured semiquantitative RT-PCR in 8 additional NSCLC tissues, and our by Giemsa staining and MTT assay in triplicate. The target sequences of the panel of 15 NSCLC cell lines and 2 normal human cells including synthetic oligonucleotides for RNAi were as follows: control1 (EGFP: gene, a SAEC, and then confirmed its increased expression in all of the 8 mutant of Aequorea victoria GFP), 5Ј-GAAGCAGCACGACTTCTTC-3Ј; control2 (Luciferase: Photinus pyralis luciferase gene), 5Ј-CGTACGCG- primary tumors and in 11 of the 15 cell lines examined (Fig. 1). GAATACTTCGA-3Ј; and control3 (Scramble: Chloroplast Euglena gracilis Growth-Inhibitory Effect of AS S-Oligonucleotides and siRNA gene coding for the 5S and 16S rRNA), 5Ј-GCGCGCTTTGTAGGATTCG-3Ј; Designed to Reduce Expression of COX17 in NSCLC Cells. To COX17-siRNA1, 5Ј-GTGACTGCGGACGAATCGG-3Ј; COX17-siRNA2, 5Ј- assess whether COX17 plays a role in growth or survival of lung GGAGAAGAACACTGTGGAC-3Ј. To validate our RNAi system, individual cancer cells, we synthesized a pair of R (control) and AS S- control siRNAs (EGFP, Luciferase, and Scramble) were initially confirmed oligonucleotides corresponding to the COX17 sequence and trans- using semiquantitative RT-PCR to decrease the expression of the correspond- fected each of them into A549 cells, a line that had shown a high ing target genes that had been transiently transfected to COS-7 cells. Down- regulation of the COX17 expression by effective siRNA but not by controls level of COX17 expression. Introduction of the AS S-oligonucleo- was also confirmed with semiquantitative RT-PCR in the cell lines used for tide decreased the number of foci formed and also decreased cell this assay. viability, compared with the control nucleotide, suggesting that Immunocytochemical Analysis.
Load more

Recommended publications
  • COX17 (NM 005694) Human Tagged ORF Clone Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn Product datasheet for RC210756 COX17 (NM_005694) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: COX17 (NM_005694) Human Tagged ORF Clone Tag: Myc-DDK Symbol: COX17 Vector: pCMV6-Entry (PS100001) E. coli Selection: Kanamycin (25 ug/mL) Cell Selection: Neomycin ORF Nucleotide >RC210756 representing NM_005694 Sequence: Red=Cloning site Blue=ORF Green=Tags(s) TTTTGTAATACGACTCACTATAGGGCGGCCGGGAATTCGTCGACTGGATCCGGTACCGAGGAGATCTGCC GCCGCGATCGCC ATGCCGGGTCTGGTTGACTCAAACCCTGCCCCGCCTGAGTCTCAGGAGAAGAAGCCGCTGAAGCCCTGCT GCGCTTGCCCGGAGACCAAGAAGGCGCGCGATGCGTGTATCATCGAGAAAGGAGAAGAACACTGTGGACA TCTAATTGAGGCCCACAAGGAATGCATGAGAGCCCTAGGATTTAAAATA ACGCGTACGCGGCCGCTCGAGCAGAAACTCATCTCAGAAGAGGATCTGGCAGCAAATGATATCCTGGATT ACAAGGATGACGACGATAAGGTTTAA Protein Sequence: >RC210756 representing NM_005694 Red=Cloning site Green=Tags(s) MPGLVDSNPAPPESQEKKPLKPCCACPETKKARDACIIEKGEEHCGHLIEAHKECMRALGFKI TRTRPLEQKLISEEDLAANDILDYKDDDDKV Chromatograms: https://cdn.origene.com/chromatograms/mk8114_f02.zip Restriction Sites: SgfI-MluI This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 4 COX17 (NM_005694) Human Tagged ORF Clone – RC210756 Cloning Scheme: Plasmid Map: ACCN: NM_005694 ORF Size: 189 bp This product is
    [Show full text]
  • Mouse Anti-Human COX17 Monoclonal Antibody, Clone 5H3 (CABT-B10023) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use
    Mouse anti-Human COX17 monoclonal antibody, clone 5H3 (CABT-B10023) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Immunogen COX17 (NP_005685,2a.a. ~ 63 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. Isotype IgG2b Source/Host Mouse Species Reactivity Human Clone 5H3 Conjugate Unconjugated Applications WB, IHC, sELISA, ELISA Sequence Similarities MPGLVDSNPAPPESQEKKPLKPCCACPETKKARDACIIEKGEEHCGHLIEAHKECMRALGFKI Format Liquid Buffer In 1x PBS, pH 7.2 Storage Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. BACKGROUND Introduction Cytochrome c oxidase (COX), the terminal component of the mitochondrial respiratory chain, catalyzes the electron transfer from reduced cytochrome c to oxygen. This component is a heteromeric complex consisting of 3 catalytic subunits encoded by mitochondrial genes and multiple structural subunits encoded by nuclear genes. The mitochondrially-encoded subunits function in electron transfer, and the nuclear-encoded subunits may function in the regulation and assembly of the complex. This nuclear gene encodes a protein which is not a structural subunit, but may be involved in the recruitment of copper to mitochondria for incorporation into the COX apoenzyme. This protein shares 92% amino acid sequence identity with mouse and rat Cox17 proteins. This gene is no longer considered to be a candidate gene for COX deficiency. A pseudogene COX17P has been found on chromosome 13. [provided by RefSeq, Jul 2008] 45-1 Ramsey
    [Show full text]
  • Genome-Wide Identification of Mrnas Associated with the Protein SMN Whose Depletion Decreases Their Axonal Localization
    Downloaded from rnajournal.cshlp.org on October 2, 2021 - Published by Cold Spring Harbor Laboratory Press Genome-wide identification of mRNAs associated with the protein SMN whose depletion decreases their axonal localization FLORENCE RAGE,1,2,3 NAWAL BOULISFANE,1,2,3 KHALIL RIHAN,1,2,3 HENRY NEEL,1,2,3,4 THIERRY GOSTAN,1,2,3 EDOUARD BERTRAND,1,2,3 RÉMY BORDONNÉ,1,2,3 and JOHANN SORET1,2,3,5 1Institut de Génétique Moléculaire de Montpellier UMR 5535, 34293 Montpellier Cedex 5, France 2Université Montpellier 2, 34095 Montpellier Cedex 5, France 3Université Montpellier 1, 34967 Montpellier Cedex 2, France ABSTRACT Spinal muscular atrophy is a neuromuscular disease resulting from mutations in the SMN1 gene, which encodes the survival motor neuron (SMN) protein. SMN is part of a large complex that is essential for the biogenesis of spliceosomal small nuclear RNPs. SMN also colocalizes with mRNAs in granules that are actively transported in neuronal processes, supporting the hypothesis that SMN is involved in axonal trafficking of mRNPs. Here, we have performed a genome-wide analysis of RNAs present in complexes containing the SMN protein and identified more than 200 mRNAs associated with SMN in differentiated NSC-34 motor neuron-like cells. Remarkably, ∼30% are described to localize in axons of different neuron types. In situ hybridization and immuno-fluorescence experiments performed on several candidates indicate that these mRNAs colocalize with the SMN protein in neurites and axons of differentiated NSC-34 cells. Moreover, they localize in cell processes in an SMN-dependent manner. Thus, low SMN levels might result in localization deficiencies of mRNAs required for axonogenesis.
    [Show full text]
  • Regulation of COX Assembly and Function by Twin CX9C Proteins—Implications for Human Disease
    cells Review Regulation of COX Assembly and Function by Twin CX9C Proteins—Implications for Human Disease Stephanie Gladyck 1, Siddhesh Aras 1,2, Maik Hüttemann 1 and Lawrence I. Grossman 1,2,* 1 Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI 48201, USA; sgladyck@med.wayne.edu (S.G.); saras@wayne.edu (S.A.); mhuttema@med.wayne.edu (M.H.) 2 Perinatology Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, Maryland and Detroit, MI 48201, USA * Correspondence: lgrossman@wayne.edu Abstract: Oxidative phosphorylation is a tightly regulated process in mammals that takes place in and across the inner mitochondrial membrane and consists of the electron transport chain and ATP synthase. Complex IV, or cytochrome c oxidase (COX), is the terminal enzyme of the electron transport chain, responsible for accepting electrons from cytochrome c, pumping protons to contribute to the gradient utilized by ATP synthase to produce ATP, and reducing oxygen to water. As such, COX is tightly regulated through numerous mechanisms including protein–protein interactions. The twin CX9C family of proteins has recently been shown to be involved in COX regulation by assisting with complex assembly, biogenesis, and activity. The twin CX9C motif allows for the import of these proteins into the intermembrane space of the mitochondria using the redox import machinery of Mia40/CHCHD4. Studies have shown that knockdown of the proteins discussed in this review results in decreased or completely deficient aerobic respiration in experimental models ranging from yeast to human cells, as the proteins are conserved across species.
    [Show full text]
  • A 5 Cytosine Binding Pocket in Puf3p Specifies Regulation Of
    A5؅ cytosine binding pocket in Puf3p specifies regulation of mitochondrial mRNAs Deyu Zhua,1, Craig R. Stumpfb,1, Joseph M. Krahna, Marvin Wickensb,2, and Traci M. Tanaka Halla,2 aLaboratory of Structural Biology, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709; and bDepartment of Biochemistry, University of Wisconsin-Madison, Madison, WI 53706 Edited by Keith R. Yamamoto, University of California, San Francisco, CA, and approved October 2, 2009 (received for review November 26, 2008) A single regulatory protein can control the fate of many mRNAs biological importance of the RNA base at the Ϫ2 position for with related functions. The Puf3 protein of Saccharomyces cerevi- regulation in vivo. siae is exemplary, as it binds and regulates more than 100 mRNAs that encode proteins with mitochondrial function. Here we eluci- Results date the structural basis of that specificity. To do so, we explore the General Puf3p Architecture and the Core Region. Crystal structures crystal structures of Puf3p complexes with 2 cognate RNAs. The key of the RNA-binding domain of Puf3p in complex with the determinant of Puf3p specificity is an unusual interaction between COX17 mRNA sequences for binding site A, CUUGUAUAUA, a distinctive pocket of the protein with an RNA base outside the and site B, CCUGUAAAUA (Fig. 1A), were determined at a ‘‘core’’ PUF-binding site. That interaction dramatically affects bind- resolution of 3.2 and 2.5 Å, respectively. Puf3p interacts with the ing affinity in vitro and is required for regulation in vivo. The Puf3p 8 bases of COX17 mRNA starting from the conserved UGUA structures, combined with those of Puf4p in the same organism, sequence much as human Pumilio1 (PUM1) binds to the equiv- illuminate the structural basis of natural PUF-RNA networks.
    [Show full text]
  • Mitochondrial Copper Homeostasis in Mammalian Cells
    Mitochondrial copper homeostasis in mammalian cells Dissertation zur Erlangung des akademischen Grades Doctor rerum naturalium (Dr. rer. nat.) vorgelegt der Fakultät Mathematik und Naturwissenschaften der Technischen Universität Dresden von Corina Oswald (Diplom-Biochemikerin) geboren am 10.04.1981 in Dohna, Deutschland Gutachter: Prof. Dr. Gerhard Rödel Prof. Dr. Alexander Storch Eingereicht am 30. April 2010 Verteidigt am 13. August 2010 ACKNOWLEDGEMENTS I sincerely thank my supervisor Prof. Dr. Gerhard Rödel for giving me the opportunity to do my PhD in his group and to join the Dresden International Graduate School for Biomedicine and Bioengineering (DIGS-BB). He introduced me to the world of mitochondria, supported and provided me with all resources and comprehension necessary to conduct my research. I thank Dr. Udo Krause-Buchholz for his scientific advice and for helping writing the paper by giving constructive comments on the manuscript. I honestly thank my TAC members Dr. Frank Buchholz and Prof. Dr. Alexander Storch for their interest in this work, for guiding me scientifically, and for stimulating discussions in the TAC meeting. Especially, Dr. Frank Bucholz for giving insightful suggestions as RNAi specialist, and Prof. Dr. Alexander Storch for acting as reviewer of this thesis. The dSTORM images would not have been possible without the very friendly collaboration with Prof. Dr. Markus Sauer and Sebastian van de Linde, Institute for Applied Laser Physics and Laser Spectroscopy of the University of Bielefeld. Thank you! I am furthermore grateful to all former and present lab members for the friendly working atmosphere, for fruitful discussions, for providing advice and assistance in many situations.
    [Show full text]
  • Original Article Stable COX17 Downregulation Leads To
    Original Article Stable COX17 Downregulation Leads to Alterations in Mitochondrial Ultrastructure, Decreased Copper Content and Impaired Cytochrome c Oxidase Biogenesis in HEK293 Cells (Cox17 protein / copper chaperone / cytochrome c oxidase assembly / mitochondrial ultrastructure) M. VANIŠOVÁ, D. BURSKÁ, J. KŘÍŽOVÁ, T. DAŇHELOVSKÁ, Ž. DOSOUDILOVÁ, J. ZEMAN, L. STIBŮREK, H. HANSÍKOVÁ Laboratory for Study of Mitochondrial Disorders, Department of Paediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic Abstract. Cox17 is an assembly factor that par- COX17 shRNA-downregulated HEK293 cell lines ticipates in early cytochrome c oxidase (COX, CcO) that have less than 10 % of the residual Cox17 pro- assembly stages. Cox17 shuttles copper ions from the tein level. Cox17-depleted cell lines exhibited decreased cytosol to the mitochondria and, together with Sco1 intramitochondrial copper content, decreased CcO and Sco2, provides copper ions to the Cox1 and Cox2 subunit levels (Cox1, Cox4 and Cox5a) and accumu- mitochondrially encoded subunits. In Saccharomyces lation of CcO subcomplexes. Similarly to yeast cells, cerevisiae, Cox17 also modulates mitochondrial mem- mitochondria in Cox17-downregulated HEK293 cell brane architecture due to the interaction of Cox17 lines exhibited ultrastructural changes including with proteins of the MICOS complex (mitochondrial cristae reduction and mitochondrial swelling. Charac- contact site and cristae organizing system). There is terization of the molecular pathogenesis of long-term currently no data regarding the impact of long-term Cox17 deficiency complements our knowledge of the Cox17 deficiency in human cells. Here, we present mitochondrial copper metabolism and assembly of construction and characterization of three stable cytochrome c oxidase in human cells.
    [Show full text]
  • Downloaded Per Proteome Cohort Via the Web- Site Links of Table 1, Also Providing Information on the Deposited Spectral Datasets
    www.nature.com/scientificreports OPEN Assessment of a complete and classifed platelet proteome from genome‑wide transcripts of human platelets and megakaryocytes covering platelet functions Jingnan Huang1,2*, Frauke Swieringa1,2,9, Fiorella A. Solari2,9, Isabella Provenzale1, Luigi Grassi3, Ilaria De Simone1, Constance C. F. M. J. Baaten1,4, Rachel Cavill5, Albert Sickmann2,6,7,9, Mattia Frontini3,8,9 & Johan W. M. Heemskerk1,9* Novel platelet and megakaryocyte transcriptome analysis allows prediction of the full or theoretical proteome of a representative human platelet. Here, we integrated the established platelet proteomes from six cohorts of healthy subjects, encompassing 5.2 k proteins, with two novel genome‑wide transcriptomes (57.8 k mRNAs). For 14.8 k protein‑coding transcripts, we assigned the proteins to 21 UniProt‑based classes, based on their preferential intracellular localization and presumed function. This classifed transcriptome‑proteome profle of platelets revealed: (i) Absence of 37.2 k genome‑ wide transcripts. (ii) High quantitative similarity of platelet and megakaryocyte transcriptomes (R = 0.75) for 14.8 k protein‑coding genes, but not for 3.8 k RNA genes or 1.9 k pseudogenes (R = 0.43–0.54), suggesting redistribution of mRNAs upon platelet shedding from megakaryocytes. (iii) Copy numbers of 3.5 k proteins that were restricted in size by the corresponding transcript levels (iv) Near complete coverage of identifed proteins in the relevant transcriptome (log2fpkm > 0.20) except for plasma‑derived secretory proteins, pointing to adhesion and uptake of such proteins. (v) Underrepresentation in the identifed proteome of nuclear‑related, membrane and signaling proteins, as well proteins with low‑level transcripts.
    [Show full text]
  • Identification of COX17 As a Therapeutic Target for Non-Small Cell Lung Cancer1
    [CANCER RESEARCH 63, 7038–7041, November 1, 2003] Advances in Brief Identification of COX17 as a Therapeutic Target for Non-Small Cell Lung Cancer1 Chie Suzuki, Yataro Daigo, Takefumi Kikuchi, Toyomasa Katagiri, and Yusuke Nakamura2 Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan Abstract Saccharomyces cerevisiae (7, 8). Although this small protein has been cloned or purified from mammals as well, including human, mouse, We have been investigating gene expression profiles in non-small cell and pig, its function in cancer cells or even in normal mammalian lung cancers (NSCLCs) to identify molecules involved in pulmonary somatic cells has not been established (8–10). carcinogenesis and select which genes or gene products might be useful as diagnostic markers or targets for new molecular therapies. Here we report Here we report functional characterization of COX17 in human evidence that the cytochrome c oxidase (CCO) assembly protein COX17 is lung tumors and in metabolism of normal mammalian cells. Our a potential molecular target for treatment of lung cancers. By semiquan- results suggest that overexpression of COX17 plays a significant role titative reverse transcription-PCR, we documented increased expression in development/progression of lung cancer and that this molecule of COX17 in all of 8 primary NSCLCs and in 11 of 15 NSCLC cell lines represents a potential target for development of novel therapeutic examined, by comparison with normal lung tissue. Treatment of NSCLC drugs. cells with antisense S-oligonucleotides or vector-based small interfering RNAs of COX17 suppressed expression of COX17 and also the activity of Materials and Methods CCO, and suppressed growth of the cancer cells.
    [Show full text]
  • Mapping the Functional Interaction of Sco1 and Cox2 in Cytochrome Oxidase Biogenesis Kevin Rigby University of Utah Health Sciences Center
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Biochemistry -- Faculty Publications Biochemistry, Department of 2008 Mapping the Functional Interaction of Sco1 and Cox2 in Cytochrome Oxidase Biogenesis Kevin Rigby University of Utah Health Sciences Center Paul A. Cobine University of Utah Health Sciences Center Oleh Khalimonchuk University of Nebraska-Lincoln, okhalimonchuk2@unl.edu Dennis R. Winge University of Utah Health Sciences Center Follow this and additional works at: http://digitalcommons.unl.edu/biochemfacpub Part of the Biochemistry Commons, Biotechnology Commons, and the Other Biochemistry, Biophysics, and Structural Biology Commons Rigby, Kevin; Cobine, Paul A.; Khalimonchuk, Oleh; and Winge, Dennis R., "Mapping the Functional Interaction of Sco1 and Cox2 in Cytochrome Oxidase Biogenesis" (2008). Biochemistry -- Faculty Publications. 243. http://digitalcommons.unl.edu/biochemfacpub/243 This Article is brought to you for free and open access by the Biochemistry, Department of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Biochemistry -- Faculty Publications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 283, NO. 22, pp. 15015–15022, May 30, 2008 © 2008 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A. Mapping the Functional Interaction of Sco1 and Cox2 in Cytochrome Oxidase Biogenesis*□S Received for publication, December 10, 2007, and in revised form, March 19, 2008 Published, JBC Papers in Press, April 7, 2008, DOI 10.1074/jbc.M710072200 Kevin Rigby, Paul A. Cobine, Oleh Khalimonchuk, and Dennis R. Winge1 From the Departments of Medicine and Biochemistry, University of Utah Health Sciences Center, Salt Lake City, Utah 84132 Sco1 is implicated in the copper metallation of the CuA site in IMS.
    [Show full text]
  • Functions of Cytochrome C Oxidase Assembly Factors
    International Journal of Molecular Sciences Review Functions of Cytochrome c Oxidase Assembly Factors Shane A. Watson and Gavin P. McStay * Department of Biological Sciences, Faculty of School of Life Sciences and Education, Staffordshire University, Science Centre, Leek Road, Stoke-on-Trent ST4 2DF, UK; w032424h@student.staffs.ac.uk * Correspondence: gavin.mcstay@staffs.ac.uk; Tel.: +44-01782-295741 Received: 17 September 2020; Accepted: 23 September 2020; Published: 30 September 2020 Abstract: Cytochrome c oxidase is the terminal complex of eukaryotic oxidative phosphorylation in mitochondria. This process couples the reduction of electron carriers during metabolism to the reduction of molecular oxygen to water and translocation of protons from the internal mitochondrial matrix to the inter-membrane space. The electrochemical gradient formed is used to generate chemical energy in the form of adenosine triphosphate to power vital cellular processes. Cytochrome c oxidase and most oxidative phosphorylation complexes are the product of the nuclear and mitochondrial genomes. This poses a series of topological and temporal steps that must be completed to ensure efficient assembly of the functional enzyme. Many assembly factors have evolved to perform these steps for insertion of protein into the inner mitochondrial membrane, maturation of the polypeptide, incorporation of co-factors and prosthetic groups and to regulate this process. Much of the information about each of these assembly factors has been gleaned from use of the single cell eukaryote Saccharomyces cerevisiae and also mutations responsible for human disease. This review will focus on the assembly factors of cytochrome c oxidase to highlight some of the outstanding questions in the assembly of this vital enzyme complex.
    [Show full text]
  • Coexpression Networks Based on Natural Variation in Human Gene Expression at Baseline and Under Stress
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations Fall 2010 Coexpression Networks Based on Natural Variation in Human Gene Expression at Baseline and Under Stress Renuka Nayak University of Pennsylvania, nayakr@mail.med.upenn.edu Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Computational Biology Commons, and the Genomics Commons Recommended Citation Nayak, Renuka, "Coexpression Networks Based on Natural Variation in Human Gene Expression at Baseline and Under Stress" (2010). Publicly Accessible Penn Dissertations. 1559. https://repository.upenn.edu/edissertations/1559 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/1559 For more information, please contact repository@pobox.upenn.edu. Coexpression Networks Based on Natural Variation in Human Gene Expression at Baseline and Under Stress Abstract Genes interact in networks to orchestrate cellular processes. Here, we used coexpression networks based on natural variation in gene expression to study the functions and interactions of human genes. We asked how these networks change in response to stress. First, we studied human coexpression networks at baseline. We constructed networks by identifying correlations in expression levels of 8.9 million gene pairs in immortalized B cells from 295 individuals comprising three independent samples. The resulting networks allowed us to infer interactions between biological processes. We used the network to predict the functions of poorly-characterized human genes, and provided some experimental support. Examining genes implicated in disease, we found that IFIH1, a diabetes susceptibility gene, interacts with YES1, which affects glucose transport. Genes predisposing to the same diseases are clustered non-randomly in the network, suggesting that the network may be used to identify candidate genes that influence disease susceptibility.
    [Show full text]